Question Bank › Recently unlocked door

Recently unlocked door

Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business

Calls Tested
499
Answered YES
24
Hit Rate
4.8%
rare by design

ICL Group Ltd (ICL) — this company's answers

NO on the Q3 2022 call 2022-11-09 B+
The model's full reasoning — Q3 2022 call → NO我们只需要根据提供的电话会议记录回答是或否。寻找管理层描述最近获得许可、批准、认证、认证、上市或准入权（由外部机构、客户、合作伙伴或机构授予）并已开始产生首批业务，且大部分准入仍在前方的证据。 扫描记录：“我们最近获得了什么吗？” 记录中提到了“美国能源部授予我们1.97亿美元”用于锂铁磷酸盐工厂。这是否是一项准入权？这是一种拨款，而非准入权。它使公司能够建厂，但这不是销售或运营许可。此外，它并未描述首批业务已经流动。 有一个关于巴西认证的提及：“我们还获得了农业部第二家研究机构的认证。该认证是独特的，因为它专门针对植物营养领域，并允许我们扩大新型肥料和生物肥料等的创新力度。” 这听起来像是一项认证/认证，可能授予了某种准入权。但这是否“最近”获得？它出现在本季度更新的上下文中。它是否允许公司销售或运营？它允许扩大创新力度，但并未明确描述首批业务已经流动。该认证允许研发，而非销售。 另一个关于“eqo.x”产品的提及：“eqo.x是同类产品中首个提供控释肥料的产品，该肥料可快速生物降解，并专门设计用于满足2026年生效的未来欧洲肥料标准。” 这似乎是产品特性，而非认证。 关于“FruitMag”的提及：“本周我们正式推出了FruitMag，这是一种食品级镁产品，可替代目前用于保护柑橘类水果免受腐烂的有毒杀菌剂。” 这似乎是一种产品发布，而非准入权。 关于“与欧洲客户签订长期钾肥协议”的提及：“本季度，我们与欧洲客户签订了一项长期钾肥协议，每年供应30万吨。” 这是一份协议，不是来自外部机构的准入权。它可能允许向该客户销售，但这是合同，不是监管批准。另外，这是否“最近”且“首批业务已流动”？该协议是新的，但记录中未提及该合同下的首批发货。 关于“美国能源部拨款”的提及：这实际上是批准，但它是资金，而非准入权。另外，它描述的是计划于2024年投入运营的工厂，因此尚无业务。 管理层是否描述了一项新认证或认证允许了新销售，且首批业务已开始？记录中未明确提到任何此类批准及已产生的收入。提到了“巴西第二家研究机构的认证”，但这是用于研发，而非销售准入。此外，它未描述经此认证的业务。 因此，答案应为否。 最终答案：否

← Back to the full ICL analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something granted by an outside authority, customer, partner, or institution that newly allows the company to sell, serve, or operate where it previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what the access permits still ahead? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) the access is REAL AND RECENTLY IN HAND — granted, completed, or effective within roughly the last few quarters, not pending, applied-for, or expected; the form may be a regulatory approval or clearance, a customer or platform qualification, a certification or accreditation, a license, a formulary or program listing, entry onto an approved-supplier roster, or any equivalent gate that previously excluded the company; (2) FIRST BUSINESS IS ALREADY FLOWING — actual initial orders, customers, shipments, enrollments, placements, or revenue attributable to the new access, occurring now, however small; and (3) management conveys that what the access opens is LARGE RELATIVE TO WHAT HAS FLOWED SO FAR — the population, market, or activity now reachable is mostly unserved, so the reported results reflect only the first trickle through the door. Answer NO if the access is still pending, hoped for, or contingent. NO if the gate was cleared but nothing has yet transacted through it. NO if the access is routine renewal of permissions the company has long held. NO if the business through the new access is already mature and substantially reflected in results. NO if the door and its significance appear only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
RDCM RADCOM Ltd. Q4 2023 2024-01-31 A
PFE Pfizer Inc. Q4 2023 2024-01-30 F
NVAX Novavax, Inc. Q3 2023 2023-11-09 F
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
CDXC ChromaDex Corporation Q4 2021 2022-03-09 C+
VNDA Vanda Pharmaceuticals Inc. Q4 2021 2022-02-23 F
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
AMGN Amgen Inc. Q3 2018 2018-10-30 B+
MAS Masco Corporation Q3 2018 2018-10-30 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
BMY Bristol-Myers Squibb Company Q4 2016 2017-01-26 F
MAT Mattel, Inc. Q3 2016 2016-10-19 C

How the model reasoned

NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.

More from the question bank

Paid to expand: the company's growth spendinTwo-sided intensityNamed catch-up gapNew leadership already changing what the comThe product is disappearing into reorder rhyComing out of the tunnelAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.